成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 1001645-58-4 Chemical Structure| 1001645-58-4
Chemical Structure| 1001645-58-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 1001645-58-4

,{[proInfo.pro_purity]}

SRT 1720 (x hydrochloride) is a biochemical reagent used as a biological material or organic compound for life science research.

Synonyms: SRT1720; SIRT-1933; CAY10559

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of SRT 1720 HCl

CAS No. :1001645-58-4
Formula : C25H23N7OS.xHCl
M.W : 506.02 (monohydrochloride basis)
SMILES Code : O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=CC=CC=C6N=C5.[H]Cl
Synonyms :
SRT1720; SIRT-1933; CAY10559
MDL No. :MFCD18074509
InChI Key :DTGRRMPPXCRRIM-UHFFFAOYSA-N
Pubchem ID :25232708

Safety of SRT 1720 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SRT 1720 HCl

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
primary hepatocytes 1 μM 1 hour Induction of SIRT1 activity reduced amounts of acetylated CRTC2 and lowered Ad-CRE-luc activity PMC2597669
HepG2 cells 5 μM SRT1720 increases FGF21 protein production and elevates CPT1α gene expression, while also increasing mitochondrial oxygen consumption rate (OCR) PMC4228483
IDG-SW3 cells 1 μM 5 days SRT1720 treatment increased the osteogenic differentiation capacity of IDG-SW3 cells and decreased sclerostin expression levels. PMC6028485
MDS-L cells 2.5 μM 96 hours To evaluate the effect of SRT1720 on the viability of MDS-L cells, results showed that SRT1720 treatment inhibited the growth of MDS-L cells. PMC6143172
MDS CD34+ cells 2.5 μM 72 hours To evaluate the effect of SRT1720 on the colony-forming ability of MDS CD34+ cells, results showed that SRT1720 treatment significantly reduced the colony formation of MDS CD34+ cells. PMC6143172

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mice Activity-based anorexia (ABA) model Intraperitoneal injection 3 mg/kg Single injection, lasting 4 hours SRT1720 made mice more susceptible to the ABA model, resulting in faster weight loss. PMC7272424
mice wild-type mice intraperitoneal injection 50 mg/kg/day once a day, 5 days per week, for 4 consecutive weeks SRT1720 treatment resulted in increased bone mass, decreased sclerostin expression, and enhanced WNT/β-catenin signaling in wild-type mice. PMC6028485
Mice NSGS mice Oral 100 mg/kg once daily for 10 consecutive days To evaluate the effect of SRT1720 on the engraftment of MDS-L cells in NSGS mice, results showed that SRT1720 treatment significantly reduced the engraftment of MDS-L cells in the bone marrow. PMC6143172
Mice Emphysema model Oral 100 mg/kg/day Once daily for 2 weeks SRT1720, by activating SIRT1, attenuated elastase-induced airspace enlargement and lung function impairment, and improved arterial oxygen saturation. PMC3366403
mice NSGS mice oral 100 mg/kg Once daily for 10 weeks To evaluate the effect of SRT1720 on the engraftment of MDS-L cells in NSGS mice, results showed that SRT1720 treatment significantly reduced the engraftment of MDS-L cells PMC6143172
Mice Activity-based anorexia (ABA) model Intraperitoneal injection 100 mg/kg/day once daily for 2 weeks SRT1720 activates SIRT1, accelerating ABA phenotypes and making mice more susceptible to ABA-related behaviors. PMC7272424
Mice Emphysema model Oral 35 mg/kg Once daily for 30 days SRT1720 attenuated elastase-induced airspace enlargement and lung function impairment as well as improved arterial oxygen saturation during emphysema development. PMC3366403

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.88mL

1.98mL

0.99mL

19.76mL

3.95mL

1.98mL

References

 

Historical Records

Categories